{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T09:48:50Z","timestamp":1723542530854},"reference-count":71,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2008,6,28]],"date-time":"2008-06-28T00:00:00Z","timestamp":1214611200000},"content-version":"vor","delay-in-days":1824,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the American Academy of Nurse Practitioners"],"published-print":{"date-parts":[[2003,7]]},"abstract":"<jats:p>Purpose<\/jats:p><jats:p>To review the variables that greatly affect adherence to the complex treatment regimens used in HIV disease and to examine available options that could improve patient outcomes.<\/jats:p><jats:p>Data Sources<\/jats:p><jats:p>Comprehensive review of current medical and scientific literature, drug\u2010prescribing literature, and randomized clinical trials of drug treatments.<\/jats:p><jats:p>Conclusions<\/jats:p><jats:p>Effective treatment of HIV infection is dependent on consistent adherence to prescribed antiretroviral medications. A large pill burden, multiple daily doses, and adverse events are some of the complexities that negatively impact patient adherence. For example, lipodystrophy and hyperlipidemia are two serious side effects associated with some agents. Once\u2010daily antiretroviral agents offer many advantages over historical treatment options but are associated with possible drawbacks.<\/jats:p><jats:p>Implications for Practice<\/jats:p><jats:p>Currently, four single agents are available for once\u2010daily administration, and a few others are under investigation. In addition, combination therapy with either dual or boosted protease inhibitor regimens is becoming a popular way of overcoming the poor pharmacokinetic characteristics of individual protease inhibitors.<\/jats:p>","DOI":"10.1111\/j.1745-7599.2003.tb01313.x","type":"journal-article","created":{"date-parts":[[2008,2,12]],"date-time":"2008-02-12T09:57:23Z","timestamp":1202810243000},"page":"305-312","source":"Crossref","is-referenced-by-count":6,"title":["Simplified Regimens for Treating HIV Infection and AIDS"],"prefix":"10.1111","volume":"15","author":[{"given":"Peter J.","family":"Piliero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph P.","family":"Colagreco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,6,28]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200003100-00008"},{"key":"e_1_2_1_3_1","unstructured":"Baril J. Polland R. B. Raffi R. Whelden M. Rutkiewicz V. &Brett\u2010Smith H.(2002 July).Stavudine extended\/prolonged release (XR\/PRC) vs. stavudine immediate release (IR) in combination with lamivudine and efavirenz: 48 week efficacy and safety.Paper presented at the XIV International AIDS Conference Barcelona Spain."},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199936040-00004"},{"key":"e_1_2_1_5_1","unstructured":"Bonnet E. P. P. Yovanovitch J. D. Mularczyk M. B. Herv\u00e9 R. Labau E. Perret B. et al.(2000).Switching from protease inhibitors to efavirenz does not improve clinical lipodystrophy and hyperlipidemia in HIV\u2010infected patients. Abstract 1538 retrieved September 28 2000 fromhttp:www.abstract\u2010sonline.com\/viewer\/vi.ract.aspcontrolNumber=25840."},{"key":"#cr-split#-e_1_2_1_6_1.1","unstructured":"Bowonwatanuwong C. Mootsikapun P. Supparatpinyo K. Tansuphaswadikul S. Athisegran R. Pasook P. et al.(2001).A randomized open label study to investigate abacavir (ABC) and lamivudine (3TC) as once daily"},{"key":"#cr-split#-e_1_2_1_6_1.2","unstructured":"(QD) components of a triple combination regimen (EPV40001). Abstract 4 retrieved February 22 2002 fromhttp:www.ias.se\/abstract\/show.aspabstract_id=4.."},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200140090-00005"},{"key":"e_1_2_1_8_1","unstructured":"Cahn P. Pantaleo G. Gatell J. Squires K. Percival L. Piliero P. et al.(2002 May).Atazanavir: A once\u2010daily protease inhibitor with a Superior lipid profile.Abstract presented at the XlVth World Congress of Cardiology Sydney Australia."},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199807000-00003"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1037\/0278-6133.19.2.124"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1086\/313849"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0277-9536(99)00468-2"},{"key":"e_1_2_1_13_1","unstructured":"Colonno R. J. Hertogs K. &Limoli K.(in press). Susceptibility of atazanavir (BMS\u2010 232632) against a panel of HIV\u20101 clinical isolates resistant to one or more approved protease inhibitors.Antimicrobial Agents and Chemotherapy."},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200003310-00005"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199904160-00001"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1310\/R8M7-EQ0M-CNPW-39FC"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-199806010-00003"},{"key":"e_1_2_1_18_1","unstructured":"Eron J. Merigan T. Kilby M. Yangco B. Gleavy J. Rusnak P. et al.(2001).A 14\u2013day assessment of the safeetv pharmacokinetics and antiviral activity of T\u20101249 a peptide inhibitor of membrane fusion. Abstract 14 retrieved February 23 2001 fromhttp:www.retrroconference.org2001abstractsabstractsabstracts14.htm."},{"key":"e_1_2_1_19_1","unstructured":"Fichtenbaum C. Blaschke T. Rosenkranz S. Segal Y. Aberg J. Gerber J. et al.(2000 July).Pharmacokinetic interactions between protease inhibitors and selected HMG\u2010CoA reductase inhibitors.Abstract WeORB544 presented at the Xlll International AIDS Conference Durban South Africa."},{"key":"e_1_2_1_20_1","first-page":"S49","article-title":"Antiretroviral therapy in 1999 for antiretroviral\u2010naive individuals with HIV infection","volume":"13","author":"Fischl M. A.","year":"1999","journal-title":"AIDS"},{"issue":"1","key":"e_1_2_1_21_1","first-page":"S61","article-title":"Attaining higher goals in HIV treatment: The central importance of adherence","volume":"73","author":"Friedland G. H.","year":"1999","journal-title":"AIDS"},{"key":"e_1_2_1_22_1","unstructured":"Gallant J. E.(2001).Antiretroviral therapy: Starting continuing and fixing. Retrieved August 31 2001 fromhttp:www.medscape.comMedscapeHIVAnnualUpdate2001mhamha0 4.gall\u201001.html."},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/09540120050123783"},{"issue":"1","key":"e_1_2_1_24_1","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1742-1241.1999.tb11662.x","article-title":"Efavirenz in the management of HIV infection","volume":"53","author":"Gazzard B. G.","year":"1999","journal-title":"International Journal of Clinical Practice"},{"issue":"4","key":"e_1_2_1_25_1","first-page":"S37","article-title":"Didanosine administered once daily: Interim results of a randomized double\u2010blind study [Abstract P82]","volume":"12","author":"Gill J.","year":"1998","journal-title":"AIDS"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.9.2319-2326.2000"},{"issue":"1","key":"e_1_2_1_27_1","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1097\/00042560-200010001-00002","article-title":"Metabolic disorders among HIV\u2010infected patients treated with protease inhibitors: A review","volume":"25","author":"Graham N. M.","year":"2000","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199709113371102"},{"key":"e_1_2_1_29_1","unstructured":"Haas D. Zala C. Schrader Thiry A. McGovern R. &Schnittman S.(2001).Once\u2010daily akuanavir plus saquinavir favorably affects total cholesterol (TC) and fasting triglyceride (TG) profiles in patients failing prior PI therapy (trial AI424\u2013009 wk 24) [Slide session LB\u2010161. Retrieved March 21 2002 fromhttp:www.thebody.comconfsicaac2001lhoyle6.html."},{"key":"e_1_2_1_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199709113371101"},{"key":"e_1_2_1_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199817000-00001"},{"key":"e_1_2_1_32_1","unstructured":"Hsyu P. H. Lewis R. Tran J. Schulz\u2010Smith M. &Kerr B.(2000 July).Pharmacokinetics (PK) of nelfinavir (NFV) after once daily dosing in combination with mini\u2010doses of ritonavir (RTV) in healthy subjects.Abstract LbPeB7049 presented at the Xlll International AIDS Conference Durban South Africa."},{"key":"e_1_2_1_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0094-0143(05)70221-4"},{"key":"e_1_2_1_34_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.1999.00334.x"},{"key":"e_1_2_1_35_1","unstructured":"Kasper T. B. Arboleda C. H. Halpern M.(2000 July).The impact of patient perceptions of body shape changes and metabolic abnormalities on anti\u2010retroviral therapy.Abstract 582 presented at the Xlll International AIDS Conference Durban South Africa."},{"key":"e_1_2_1_36_1","unstructured":"Kaul S. Agarwala S. Hess H. Behr D. Nichola P. Xie J. D. et al.(2002 July).Relative bioavailability of stavudine (d4T) extended\u2010release (XR) formulation after coadministration with a light or high\u2010fat meal in healthy subjects.Paper presented at the XIV International AIDS Conference Barcelona Spain."},{"key":"e_1_2_1_37_1","unstructured":"Kearney B. P. Damle B. Plummer A. Sayre J. Zhang X. Ryan K. et al.(2002 July).Tenofovir Df (TDF) and didanosine EC (ddl EC): Investigation of pharmacokinetic (PK) drug\u2010drug and drug\u2010food interactions.Paper presented at the XIV International AIDS Conference Barcelona Spain."},{"issue":"3","key":"e_1_2_1_38_1","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1128\/AAC.41.3.654","article-title":"Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir","volume":"41","author":"Kempf D. J.","year":"1997","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"e_1_2_1_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/3293"},{"key":"e_1_2_1_40_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-131-2-199907200-00002"},{"key":"e_1_2_1_41_1","doi-asserted-by":"publisher","DOI":"10.1086\/317426"},{"issue":"3","key":"e_1_2_1_42_1","first-page":"S197","article-title":"HIV\u2010associated lipodystrophy syndrome","volume":"74","author":"Mauss S.","year":"2000","journal-title":"AIDS"},{"key":"e_1_2_1_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199714000-00002"},{"key":"e_1_2_1_44_1","unstructured":"Miller M. Johnson A. Isaacson E. &Margot N.(2001).Genotypic analyses and HIV RNA responses in patients after 96 weeks of tenofovir DF (TDF) therapy. Abstract retrieved August 20 2001 fromhttp:www.ias.se\/abstract\/show.aspabstract_id=l28.."},{"key":"e_1_2_1_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199907300-00003"},{"key":"e_1_2_1_46_1","unstructured":"Molina J. M. Perusat S. Ferchal R. Rancinan C. Raffi F. Rozenbaum W. et al.(2001).Once\u2010daily combination therapy with emtricitabine didanosine and efavirenz in treatment\u2010naive HIV\u2010infected adults: 64\u2013week follow\u2010up of the ANRS 091 Trial. Abstract 321 retrieved April 27 2001 fromhttp:www.retro\u2010conference.org2001abstractsabstractsabstracts321.htm."},{"key":"e_1_2_1_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0796-760"},{"key":"#cr-split#-e_1_2_1_48_1.1","unstructured":"Moyle G. J. Buss N. E. &Gazzard B.(2002).Pravastatin 40-mg qd does not alter protease inhibitor"},{"key":"#cr-split#-e_1_2_1_48_1.2","unstructured":"(PI) exposure or virological efficacy over 24 weeks therapy. Abstract 446-W retrieved March 13 2002 fromhttp:63.126.3.842002Abstract12992.htm."},{"key":"e_1_2_1_49_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199754060-00002"},{"key":"e_1_2_1_50_1","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200012010-00004"},{"issue":"2","key":"e_1_2_1_51_1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/00002030-200001280-00014","article-title":"Quality of life in asymptomatic and symptomatic HIV infected patients in a trial of ritonavir\/saquinavir therapy","volume":"14","author":"Nieuwkerk P. I.","year":"2000","journal-title":"AIDS"},{"key":"e_1_2_1_52_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199803263381301"},{"key":"e_1_2_1_53_1","unstructured":"Panel on Clinical Practices for Treatment of HIV Infection Convened by the Department of Health and Human Services and theHenryJ.Kaiser Family Foundation(2002).Guidelines for the use of antirefroviral agents in HIV\u2010infected adults and adolescents. Retrieved February 14 2002 fromhttp:www.hivatis.orgguidelinesadultFebO4_02Aduffidl.pdf."},{"key":"e_1_2_1_54_1","unstructured":"Pantaleo G. Sanne I. Cahn P. Percival L. Phanuphak P. Kelleher T. et al.(2002 October).Atazanavir (BMS\u2010232632): 48\u2013week safety and efficacy vs. nelfinavir each in Combination with stavudine and lamivudine in treatment\u2010naive HIV\u2010positive subjects (AI324\u2013008).Abstract 011 presented at the Eighth European Conference on Clinical Aspects and Treatment of HN Infection Athens Greece."},{"key":"e_1_2_1_55_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-133-1-200007040-00004"},{"key":"e_1_2_1_56_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200203290-00020"},{"key":"e_1_2_1_57_1","unstructured":"Piliero P. J. Cahn P. Pantaleo G. Gatell J. Squires K. Percival L. et al.(2002).Atazanavir: A once\u2010daily protease inhibitor with a superior lipid profile\u2014Results of clinical trials beyond week 48. Abstract 706\u2013T retrieved June 4 2002 fromhttp:www.retroconference.org2002Abstract13827.htm."},{"key":"e_1_2_1_58_1","unstructured":"Pollard R. B.(2000).Towards once\u2010daily antiretroviral therapy [expert column]. Retrieved January 19 2001 fromhttp:www.medscape.comMedscapeHIVjournal2000v06.n06mha1201.pollmha1201.poll\u201001.html."},{"key":"e_1_2_1_59_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.8.2093-2099.2000"},{"key":"e_1_2_1_60_1","unstructured":"Ruane P. Mendonca J. Timerman A. Cemohous P. Bauer E. Bernstein B. et al.(2001).Kaletra vs. nelfinavir in antiretroviral\u2010naive subjects: Week 60 comparison in a Phase Ill blinded randomized clinical trial. Abstract 6 retrieved September 27 2001 fromwww.ias.se\/abstract\/show.aspabstract_id=6.."},{"issue":"1","key":"e_1_2_1_61_1","first-page":"47","article-title":"Switching antiretroviral drugs for treatment of metabolic complications in HIV\u20101 infection: Summary of selected trials","volume":"10","author":"Saag M. S.","year":"2002","journal-title":"Topics in HIV Medicine"},{"key":"e_1_2_1_62_1","unstructured":"Schooley R. Myers R. Ruane P. Beall G. Lampiris H. Miller M. et al.(2000 September).Tenofovir disoproxil fumarate (TDF) for the freatment of antiretroviral experienced patients: A double\u2010blind placebo\u2010controlled study.Abstract 34690 presented at the 40th lnterscience Conference on Antimicrobial Agents and Chemotherapy Toronto Canada."},{"issue":"4","key":"e_1_2_1_63_1","first-page":"S6","article-title":"Tenofovir disoproxil fumarate (TDF) for the treatment of antiretroviral experienced patients: A 48 week analysis of a randomized, double blind, placebo\u2010controlled study [abstract PL6.3]","volume":"14","author":"Schooley R.","year":"2000","journal-title":"AIDS"},{"key":"e_1_2_1_64_1","unstructured":"Smyth C.(2001).Revised prescribing information regarding the prefemed twice\u2010daily dosing for Videx (didanmine) based on new study results. Retrieved December 26 2001 fromhttp:www.fda.govmedwatchsafe\u2010ty2000videx.htm."},{"key":"e_1_2_1_65_1","unstructured":"Staszewski S. Gallant J. Pozniak A. Suleiman J. DeJesus E. Koenig E. et al.(2002 July).Efficacy and safety of tenofovir disoproxil fumarate (TDO versus stavudine (d4T) when used in combination with lamivudine (3TC) and efavirenz (EN) in HIV\u20101 infected patients naive to antiretroviral therapy (ART): 48\u2013week interim results.Paper presented at the XIV International AIDS Conference Barcelona Spain."},{"key":"e_1_2_1_66_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.13.2050"},{"key":"e_1_2_1_67_1","unstructured":"Viciana P. Alarcon A. Martin P. Serrano L. Lopez\u2010Codes F. Cordero E. et al.(2000).Partial improvement of lipodvstmphy after switching from HIV\u20101 protease inhibitors (PI) to efavirenz (EFV). Abstract 48 retrieved 0 AD217 fromhttp:www.retroconference.org2000abstracts48.htm."},{"key":"e_1_2_1_68_1","unstructured":"Visnegarwala R. Sajja P. Fasano P. Sepcie B. &White A.(2001).Comparison of efficacy safety and tolerability of indinavir\/ritonavir (lND\/RIT) combination to indinavir (IND) alone in a community clinic. Abstract 430 retrieved August 15 2001 fromhttp:www.ias.se\/print.aspabstract_id=430.."},{"key":"e_1_2_1_69_1","unstructured":"Wenger N. Gifford A. Liu H. Chesney M. Golin C. Crstal S. et al.(1999).Patient characteristics and attitudes associated with antiretroviral (AR) adherence. Abstract 98 retrieved August 15 2001 fromhttp:www.retro\u2010conference.org1999abstracts98.htm."},{"key":"e_1_2_1_70_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.231140698"}],"container-title":["Journal of the American Academy of Nurse Practitioners"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1745-7599.2003.tb01313.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1745-7599.2003.tb01313.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T08:58:17Z","timestamp":1696669097000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1745-7599.2003.tb01313.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,7]]},"references-count":71,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2003,7]]}},"alternative-id":["10.1111\/j.1745-7599.2003.tb01313.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1745-7599.2003.tb01313.x","archive":["Portico"],"relation":{},"ISSN":["1041-2972","1745-7599"],"issn-type":[{"value":"1041-2972","type":"print"},{"value":"1745-7599","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,7]]}}}